Gregor Novak
Ljubljana University Medical Centre
23 Papers
38 Citations
Gregor Novak is an academic researcher from Ljubljana University Medical Centre. The author has contributed to research in topics: Vedolizumab & Inflammatory bowel disease. The author has an hindex of 11, co-authored 23 publications. Previous affiliations of Gregor Novak include University of Amsterdam & University of Western Ontario.
Chat about Author
Papers
Review article: dose optimisation of infliximab for acute severe ulcerative colitis.
Pieter Hindryckx,Pieter Hindryckx,Gregor Novak,Gregor Novak,N. Vande Casteele,Debby Laukens,Claire E Parker,Lisa M. Shackelton,Neeraj Narula,Reena Khanna,Parambir S. Dulai,Barrett G. Levesque,Barrett G. Levesque,W J Sandborn,W J Sandborn,Geert D'Haens,Brian G. Feagan,Vipul Jairath +17 more
TL;DR: Although optimal medical management of acute severe ulcerative colitis (UC) is ill‐defined, infliximab has become a standard of care and accumulating evidence suggests an increased rate of inflIXimab clearance in patients with acute severe UC and a reduced colectomy rate with an intensified inflixIMab induction regimen.
92
The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?
Pieter Hindryckx,Pieter Hindryckx,Niels Vande Casteele,Niels Vande Casteele,Gregor Novak,Gregor Novak,Reena Khanna,Geert D'Haens,William J. Sandborn,William J. Sandborn,Silvio Danese,Vipul Jairath,Brian G. Feagan +12 more
TL;DR: Current data on the mechanisms of action, efficacy, and safety of recently approved and late-stage pipeline therapies are reviewed, and this information is used to speculate on the positioning of these drugs, alone or in combination, in therapeutic algorithms for Crohn's disease and ulcerative colitis.
81
Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview
Pieter Hindryckx,Pieter Hindryckx,Gregor Novak,Gregor Novak,Niels Vande Casteele,Niels Vande Casteele,Reena Khanna,Debby Laukens,Vipul Jairath,Brian G. Feagan +9 more
TL;DR: A greater understanding of the pharmacokinetics of therapeutic antibodies has led to the development of new strategies to reduce immunogenicity and more efficient use ofThese preventive strategies include regular scheduled dosing with maintenance of stable therapeutic trough drug concentrations, and co-administration of an immunosuppressive.
Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn’s Disease Likely to Achieve Endoscopic and Biochemical Remission
Jurij Hanžel,Jurij Hanžel,Jurij Zdovc,Tina Kurent,Nejc Sever,Katarina Javornik,Katja Tuta,Matic Koželj,Nataša Smrekar,Gregor Novak,Borut Štabuc,Borut Štabuc,Erwin Dreesen,Debby Thomas,Tomaž Vovk,Iztok Grabnar,David Drobne,David Drobne +17 more
TL;DR: It is found that serum concentrations of ustekinumab as early as 1 hour after intravenous infusion might be used to identify patients with CD most likely to achieve endoscopic remission and this early measurement might beused to optimize treatment of CD.
36
Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn’s disease
Gregor Novak,Toer W. Stevens,Tanja van Viegen,Peter Bossuyt,Borut Štabuc,Jenny Jeyarajah,Guangyong Zou,Ingrid C. Gaemers,Trevor D. McKee,Fred Fu,Lisa M. Shackelton,Reena Khanna,Gijs R. van den Brink,William J. Sandborn,Brian G. Feagan,Rish K. Pai,Vipul Jairath,Niels Vande Casteele,Geert R. D'Haens +18 more
TL;DR: The appropriate location for biopsy procurement relative to an ulcer in active Crohn's disease is unknown.
24